Pharmacological Treatments in Pathological Gambling

Research output: Contribution to journalJournal article

Standard

Pharmacological Treatments in Pathological Gambling. / Grant, Jon E; Odlaug, Brian Lawrence; Schreiber, Liana R N.

In: British Journal of Clinical Pharmacology. Supplement, Vol. 77, No. 2, 14.09.2012, p. 375-381.

Research output: Contribution to journalJournal article

Harvard

Grant, JE, Odlaug, BL & Schreiber, LRN 2012, 'Pharmacological Treatments in Pathological Gambling', British Journal of Clinical Pharmacology. Supplement, vol. 77, no. 2, pp. 375-381. https://doi.org/10.1111/j.1365-2125.2012.04457.x

APA

Grant, J. E., Odlaug, B. L., & Schreiber, L. R. N. (2012). Pharmacological Treatments in Pathological Gambling. British Journal of Clinical Pharmacology. Supplement, 77(2), 375-381. https://doi.org/10.1111/j.1365-2125.2012.04457.x

Vancouver

Grant JE, Odlaug BL, Schreiber LRN. Pharmacological Treatments in Pathological Gambling. British Journal of Clinical Pharmacology. Supplement. 2012 Sep 14;77(2):375-381. https://doi.org/10.1111/j.1365-2125.2012.04457.x

Author

Grant, Jon E ; Odlaug, Brian Lawrence ; Schreiber, Liana R N. / Pharmacological Treatments in Pathological Gambling. In: British Journal of Clinical Pharmacology. Supplement. 2012 ; Vol. 77, No. 2. pp. 375-381.

Bibtex

@article{3a3fc69b910945e69ac69d464484c811,
title = "Pharmacological Treatments in Pathological Gambling",
abstract = "AIMS: Pathological gambling (PG) is a relatively common and often disabling psychiatric condition characterized by intrusive urges to engage in deleterious gambling behavior. Although common and financially devastating to individuals and families, there currently exist no formally approved pharmacotherapeutic interventions for this disorder. This review seeks to examine the history of medication treatments for PG. METHODS: A systematic review of the 18 double-blind, placebo-controlled pharmacotherapy studies conducted for the treatment of pathological gambling was conducted. Study outcome and the mean dose of medication administered was documented in an effort to determine a preferred medication choice in this population. RESULTS: A variety of medication classes have been examined in the treatment of PG with varying results. Antidepressants, atypical antipsychotics, and mood stabilizers have demonstrated mixed results in controlled clinical trials. Although limited information is available, opioid antagonists and glutamatergic agents have demonstrated efficacious outcomes, especially for individuals with PG suffering from intense urges to engage in the behavior. CONCLUSIONS: Given that several studies have demonstrated their efficacy in treating the symptoms associated with PG, opioid antagonists should be considered the first-line treatment for PG at this time. Most published studies, however, have employed relatively small sample sizes, are of limited duration, and involve possibly non-representative clinical groups (e.g., those without co-occurring psychiatric disorders. Response measures have varied across studies. Heterogeneity of PG treatment samples may also complicate identification of effective treatments. Identification of factors related to treatment response will help inform future studies and advance treatment strategies for PG.",
author = "Grant, {Jon E} and Odlaug, {Brian Lawrence} and Schreiber, {Liana R N}",
note = "{\circledC} 2012 The Author. British Journal of Clinical Pharmacology {\circledC} 2012 The British Pharmacological Society.",
year = "2012",
month = "9",
day = "14",
doi = "10.1111/j.1365-2125.2012.04457.x",
language = "English",
volume = "77",
pages = "375--381",
journal = "British Journal of Clinical Pharmacology. Supplement",
issn = "0264-3774",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Pharmacological Treatments in Pathological Gambling

AU - Grant, Jon E

AU - Odlaug, Brian Lawrence

AU - Schreiber, Liana R N

N1 - © 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

PY - 2012/9/14

Y1 - 2012/9/14

N2 - AIMS: Pathological gambling (PG) is a relatively common and often disabling psychiatric condition characterized by intrusive urges to engage in deleterious gambling behavior. Although common and financially devastating to individuals and families, there currently exist no formally approved pharmacotherapeutic interventions for this disorder. This review seeks to examine the history of medication treatments for PG. METHODS: A systematic review of the 18 double-blind, placebo-controlled pharmacotherapy studies conducted for the treatment of pathological gambling was conducted. Study outcome and the mean dose of medication administered was documented in an effort to determine a preferred medication choice in this population. RESULTS: A variety of medication classes have been examined in the treatment of PG with varying results. Antidepressants, atypical antipsychotics, and mood stabilizers have demonstrated mixed results in controlled clinical trials. Although limited information is available, opioid antagonists and glutamatergic agents have demonstrated efficacious outcomes, especially for individuals with PG suffering from intense urges to engage in the behavior. CONCLUSIONS: Given that several studies have demonstrated their efficacy in treating the symptoms associated with PG, opioid antagonists should be considered the first-line treatment for PG at this time. Most published studies, however, have employed relatively small sample sizes, are of limited duration, and involve possibly non-representative clinical groups (e.g., those without co-occurring psychiatric disorders. Response measures have varied across studies. Heterogeneity of PG treatment samples may also complicate identification of effective treatments. Identification of factors related to treatment response will help inform future studies and advance treatment strategies for PG.

AB - AIMS: Pathological gambling (PG) is a relatively common and often disabling psychiatric condition characterized by intrusive urges to engage in deleterious gambling behavior. Although common and financially devastating to individuals and families, there currently exist no formally approved pharmacotherapeutic interventions for this disorder. This review seeks to examine the history of medication treatments for PG. METHODS: A systematic review of the 18 double-blind, placebo-controlled pharmacotherapy studies conducted for the treatment of pathological gambling was conducted. Study outcome and the mean dose of medication administered was documented in an effort to determine a preferred medication choice in this population. RESULTS: A variety of medication classes have been examined in the treatment of PG with varying results. Antidepressants, atypical antipsychotics, and mood stabilizers have demonstrated mixed results in controlled clinical trials. Although limited information is available, opioid antagonists and glutamatergic agents have demonstrated efficacious outcomes, especially for individuals with PG suffering from intense urges to engage in the behavior. CONCLUSIONS: Given that several studies have demonstrated their efficacy in treating the symptoms associated with PG, opioid antagonists should be considered the first-line treatment for PG at this time. Most published studies, however, have employed relatively small sample sizes, are of limited duration, and involve possibly non-representative clinical groups (e.g., those without co-occurring psychiatric disorders. Response measures have varied across studies. Heterogeneity of PG treatment samples may also complicate identification of effective treatments. Identification of factors related to treatment response will help inform future studies and advance treatment strategies for PG.

U2 - 10.1111/j.1365-2125.2012.04457.x

DO - 10.1111/j.1365-2125.2012.04457.x

M3 - Journal article

C2 - 22979951

VL - 77

SP - 375

EP - 381

JO - British Journal of Clinical Pharmacology. Supplement

JF - British Journal of Clinical Pharmacology. Supplement

SN - 0264-3774

IS - 2

ER -

ID: 122546474